Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00366106
Status:
TERMINATED
Last Update Posted:
2012-04-06
First Post:
2006-08-16
Brief Title:
Alternative Schedule of VelcadeDexamethasone Plus Doxil for Patients With Multiple Myeloma
Sponsor:
Accelerated Community Oncology Research Network
Organization:
Accelerated Community Oncology Research Network
Study Overview
Official Title:
A Phase II Open Label Study Evaluating an Alternative Schedule of VelcadeDexamethasone Plus Doxil in the Treatment of Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib doxorubicin HCl liposome and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None